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When biomarker concentrations of all patient samples were plot-
ted in chronological order of assaying, it appeared that there
was a sufﬁcient window of variation within a positively skewed
distribution. In general there was no evident variation over time
and between assays, except for two remarkable observations:
For the sCOMP assay there was a clear difference in measured
biomarker concentrations between the ﬁrst 6 kits and last 8 kits.
In the ﬁrst kits measured biomarker concentrations were a 10-fold
higher and showed signiﬁcantly more variation than in the last
kits. For the sC1,2C and sCS846 assays, there was a signiﬁcant
negative correlation between the measured biomarker concentra-
tion and sample order (chronologic/position) in the assay plates,
repeatedly found for each of the assay plates.
Conclusions: Reliable biomarker measurement in this large sam-
ple set seems possible for the majority of the studied biomarkers.
However, despite attempts to minimize variation, there are some
striking challenges, presumably technical in nature. The remark-
able observations in the sCOMP assay, and the sC1,2C and
sCS846 assays need further evaluation (as is presently ongoing)
before correlations with the clinical and radiographic data sets can
be made.
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ANALYSIS OF 31 BIOMARKERS AND BIOMARKER
FACTORS IN PRE-RADIOGRAPHIC AND RADIOGRAPHIC
KNEE OSTEOARTHRITIS: RESULTS OF A POPULATION-
BASED STUDY USING MRI
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H. Wong1, A. Thorne1, J. Singer1, A.R. Poole3, P. Garnero4,
J. Kopec1, A. Guermazi5, S. Nicolaou1, J.M. Esdaile1
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Purpose: 1) To determine the association of 31 biomarkers with
pre-radiographic and radiographic symptomatic knee OA com-
pared to symptomatic controls; 2) to determine if latent biomarker
factors determined by principal components based factor analy-
sis (PC-FA) are better able to distinguish OA stage compared to
individual biomarkers. PC-FA, in addition to revealing potential un-
derlying factors, may be useful to overcome problems of multiple
comparisons and may help stabilize variance.
Methods: 255 subjects, 40-79 years, with knee pain were as-
sembled, stratiﬁed by age decade and gender, in a cross-sectional
population-based study and evaluated with MRI, xray and biomark-
ers. MR cartilage (MRC) defects (score 0-4) and x-rays (Kellgren-
Lawrence [KL] grade 0-4) were read blinded. Subjects were
classiﬁed as No OA (NOA) (KL<2, MRC=0), Pre-Radiographic
OA (PROA) (KL<2, MRC≥1) or Radiographic OA (ROA) (KL≥2,
MRC≥1). Serum levels of matrix metalloproteinases (MMPs) 1, 3
and 9, tissue inhibitor of MMP, interleukins 1a, 1b, 4, 6, 7, 8, 10,
17A, tumor necrosis factor, c-telopeptide of type I collagen (CTX-I),
adiponectin, resistin, eotaxin, C-reactive protein, hyaluronic acid
(HA) and other cytokines were evaluated. PC-FA was performed
using individual biomarkers and ratios of markers previously mea-
sured, including urine c-telopeptide of type II collagen (uCTX-II),
urine and serum type II and types I and II collagen cleavage
neoepitopes (C2C and C1,2C respectively), c-propeptide of type
II procollagen (CPII), 846 epitope, and urine n-telopeptide of type
I collagen (uNTX-I). Multicategory logistic regression (adjusted for
age, sex and BMI) was used to evaluate the association of OA cat-
egory with each log transformed biomarker, biomarker ratio, and
biomarker factor, incorporating stratum sampling weights. Stan-
dardized (i.e. per standard deviation change) odds ratios (ORs)
were reported to enable comparison of the ORs across biomarker
variables.
Results: Signiﬁcant associations with PROA vs NOA were seen
for MMP-9 (OR 1.60, 95% CI 1.00-2.57), uC2C (OR 2.34, 95% CI
1.34-4.09), uC1,2C (OR 1.99, 95% CI 1.24-3.19), and uC2C/sCPII
ratio (OR 2.41, 95% CI 1.33-4.37). Risk of ROA vs NOA was
signiﬁcantly increased for uCTX-II (OR 2.97, 95% CI 1.45-6.08),
uC2C (OR 2.28, 95% CI 1.23-4.22), uC1,2C (OR 2.08, 95%
CI 1.21-3.56), uCTX-II/sCPII (OR 2.62, 95% CI 1.35-5.06) and
uC2C/sCPII (OR 2.55, 95% CI 1.32-4.95). PC-FA identiﬁed 4 clin-
ically interpretable factors, of which one factor (determined largely
by uCTX-II, uC2C, uNTX-I, CTX-I, uC1,2C, and HA) was signif-
icantly associated with PROA (OR 2.08, 95% CI 1.04-4.14) and
with ROA (OR 2.52, 95% CI 1.22-5.20). PC-FA with inclusion of
biomarker ratios resulted in similar ﬁndings. The strength of asso-
ciation with PROA and ROA was similar for individual biomarkers,
biomarker ratios and biomarker factors.
Conclusions: In this population-based study, several biomark-
ers were signiﬁcantly associated with PROA (MMP-9, uC2C and
uC1,2C), and with ROA (uCTX-II, uC2C, uC1,2C). Discrimination
of OA groups within this cohort was not improved using biomarker
factors (determined by factor analysis) over individual biomarkers
or biomarker ratios.
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TENASCIN-C LARGE, AN ELASTIC PROTEIN INDICATING
JOINT DISEASE/INJURY IN HUMANS & PRECLINICAL
ANIMAL MODELS
L. Patel, W. Sun, S. Glasson, K.E. Georgiadis, E.A. Morris,
P.S. Chockalingam
Wyeth Res., Cambridge, MA
Purpose: Tenascin-C (TN-C) is a modular, multifunctional,
hexabrachion-shaped, elastic extra cellular matrix (ECM) glyco-
protein with binding sites for other ECM proteins. It was discovered
originally at the myotendinous junction and later found in the os-
teotendinous junction and superﬁcial layers of articular cartilage.
It plays a major role in cell adhesion & migration, and stretches
several times its resting length due to its ﬁbronectin type (FN) III
domain. TN-C is abundantly expressed in musculoskeletal tissues
during organogenesis and embryogenesis, its expression is very
restricted in healthy tissues, and reappears as a high molecular
weight splice variant in association with wound healing, inﬂamma-
tory processes, or neoplasia. TN-C has been reported to be highly
reexpressed in cartilage in diseased/injured joints. The objective
of this study was to evaluate the potential of TN-C as a marker of
joint disease/injury.
Methods: TN-C high molecular weight variants that include FN
III A-D domains were speciﬁcally detected in synovial ﬂuid (SF)
samples by the Tenascin-C Large ELISA (IBL). Human SF from
patients with end stage osteoarthritis (OA, 28), rheumatoid arthri-
tis (RA, 8), anterior cruciate ligament rupture (ACL, 8), and
knee-healthy reference subjects (Ref, 24) from NEBH/Northland
Labs/NEBH/NDRI &Northland Labs, respectively were tested in
the assay. Joint instability surgery was performed in male cross-
bred hounds, right knee had a mini-arthrotomy and anterior cruci-
ate ligament transected (ACLT), and the contralateral limb had a
’sham’ surgery with a miniarthrotomy but no generation of instabil-
ity. At 1, 3 and 6 months post-surgery, 4-6 animals per timepoint
were euthanized, and SF collected from ACLT/sham knees. Joint
instability was induced in rats (n=4-6 per group) by medial menis-
cal surgery in one knee with the other knee as a contralateral
control. SF lavage samples collected at 1, 4, and 8 wks post
surgery.
Results: TN-C levels were signiﬁcantly elevated in SF from OA (7-
fold), RA (5-fold), and ACL (3-fold) human patients as compared to
reference individuals. There was a concomitant increase in TN-C
levels in human OA cartilage (>60-fold) as compared to non-OA
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cartilage extracts. The dog ACLT model of acute injury showed
higher levels of TN-C in surgery knees at 1-month post surgery
(73-fold) and 3-months post surgery (48-fold) as compared to
control knees. Higher levels of TN-C were maintained in surgery
knees 6-months post surgery in this dog model. In the rat meniscal
tear model, there was a signiﬁcant increase (40-fold) in TN-C in
surgery knees at 1wk as compared to no surgery contralateral
controls, and this increase was maintained at 4 and 8 wks, albeit
with a smaller absolute difference from control.
Conclusions: The potential of TN-C Large as a unique biomarker
of joint disease/injury has been demonstrated using synovial ﬂuids
from humans with various joint diseases and from preclinical
animal models of joint injury. Being elastic, TN-C might play
an important role in degenerative/regenerative processes where
the normal biomechanical environment of musculoskeletal tissue
is compromised by disease/injury. As a binder of several ECM
proteins, release of TN-C could have a larger impact on the integral
structure/function of other ECM proteins, and has the potential to
be a marker of joint pathobiology and healing. Our preliminary
results indicate that TN-C levels may be applicable to determining
pharmacodynamic activity of chondro-protecting drugs in humans.
Work is ongoing to study the levels of TN-C during degeneration
in other joint tissues such as tendon. Understanding the functions
of TN-C would provide insights for pharmacologic intervention of
musculoskeletal diseases/injuries.
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DEGRADATION TO SYNTHESIS RATIOS OF TYPE II
COLLAGEN BIOMARKERS IN SYNOVIAL FLUID AND
SERUM IN THOROUGHBRED RACEHORSES
T. Trumble1, A. Nicholson1, K. Merritt2, M. Brown2
1Univ. of Minnesota, St. Paul, MN; 2Univ. of Florida, Gainesville,
FL
Purpose: Type II collagen biomarkers have shown promise in the
study of osteoarthritis. CPII (cleaved C-propeptide of type II colla-
gen) has been directly correlated with type II collagen synthesis.
CTX II (crosslinked C-telopeptide fragments of type II collagen),
C1,2C (neoepitope of types I and II collagen created after collage-
nase cleavage), and C2C (neoepitope of type II collagen created
after collagenase cleavage) have been used to assess collagen
degradation. The objective of the study was to compare type II
collagen degradation to synthesis ratios in serum and synovial
ﬂuid (SF) from normal horses and those with osteochondral (OC)
injury.
Methods: SF was taken from the carpal joints of 2 groups of
Thoroughbred racehorses: (1) normal, adult horses > 3 years of
age (2) OC injured horses 2-7 years of age undergoing arthro-
scopic surgery for removal of OC fragments resulting from racing
injury. From group 1 horses, serum was collected from 16 horses.
SF was obtained from 10 middle carpal joints (MCJ), and 10
radiocarpal joints (RCJ). From group 2, serum was collected from
20 horses. SF was collected from 10 MCJ and 10 RCJ. SF
was aseptically collected by needle arthrocentesis without lavage,
Abstract 115 – Table 1. Mean (± SD) concentrations of serum and SF type II collagen biomarkers and degradation to synthesis ratios for normal and osteochondral
(OC) injured carpal joints
Mean biomarker concentrations (± SD) Degradation:Synthesis
C2C (pmol/mL) C1,2C (pmol/mL) CTX II (pg/mL) CPII (ng/mL) C2C:CP II C1,2C:CP II CTX II:CP II
Serum
Normal 479±32.2 452±16*** 70.3±9.0** 1045±91 0.43±0.19 0.47±0.14* 0.07±0.03**
OC injured 415±9.8 580±21.6 39.6±3.4 1019±90 0.43±0.12 0.63±0.21 0.04±0.01
Synovial Fluid
Normal 274±15.6** 278±31.6*** 160±45*** 1013±60*** 0.26±0.06 0.22±0.05*** 0.08±0.05***
OC injured 409±32.6 1070±122 513±47.1 1637±110 0.26±0.09 0.65±0.37 0.37±0.28
Bolded values indicate a signiﬁcant difference between groups within serum or SF. *P≤0.05; **P≤0.01; ***P≤0.001.
centrifuged, and decanted. Commercially available ELISAs, were
used to measure type II collagen markers (C1,2C, C2C, CPII, and
CTX II). Differences between each group were evaluated using an
unpaired t-test. P<0.05 was considered signiﬁcant.
Results: Concentrations of C2C; C1,2C; and CTX II were all sig-
niﬁcantly higher in SF from OC injured joints compared to normal
joints (Table 1). Concentrations of CPII were also signiﬁcantly
higher in SF from injured joints compared to normal joints. Degra-
dation to synthesis ratios in SF were signiﬁcantly higher in OC
injured carpal joints compared to normal joints for C1,2C:CPII and
CTX II:CPII, but not for C2C:CPII. In serum, concentrations of
C1,2C were signiﬁcantly higher from OC injured horses compared
to normal horses. Serum concentrations of CTX II were signiﬁ-
cantly lower from OC injured horses compared to normal horses.
Serum ratios were signiﬁcantly higher in horses with OC injured
carpal joints compared to normal horses for C1,2C:CPII only. The
ratio was signiﬁcantly lower in serum from horses with OC injured
carpal joints compared to normal horses for CTX II:CPII only.
Conclusions: Joint injury affects concentrations of type II colla-
gen degradation and synthesis biomarkers and their ratios when
compared to normal horses. In SF, C1,2C:CPII and CTX II:CPII
ratios demonstrate that degradation predominates over synthe-
sis when the joint is injured because the ratios are higher than
normal joints. The serum C1,2C:CPII ratio suggests that there is
higher degradation after injury compared to normal horses with
no difference in the amount of synthesis. The CTX II:CPII ratio
suggests that the synthesis of type II collagen stays steady with
less degradation. However, increasing or decreasing degradation
to synthesis ratios must be interpreted in light of the known effect
of injury on biomarker concentrations in both SF and serum. Injury
may cause increase in SF concentrations, but may at the same
time cause an increase or decrease in serum concentrations.
Thus, SF biomarkers may be more indicative of degradation or
synthesis in a single joint than serum biomarkers.
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SYNOVIAL FLUID URIC ACID AS A MARKER OF JOINT
TISSUE DEGRADATION IN OSTEOARTHRITIS
T.V. Stabler, A. Heinrichs, G. McDaniel, K. Huffman, V.B. Kraus
Duke Univ. Med. Ctr., Durham, NC
Purpose: Uric acid (UA) is constitutively present in normal cells,
increased in concentration when cells are injured and released
from dying cells. The products of cell stress and tissue damage
may represent “danger signals” that function as endogenous ad-
juvants recognized by the immune system. UA has been identiﬁed
as one of these principal endogenous “danger signals” released
from injured cells. We sought to determine whether elevated syn-
ovial ﬂuid (SF) UA might be a potentiating factor in osteoarthritis
(OA).
Methods: Patients: A total of 159 participants were enrolled in
the Strategies to Predict Osteoarthritis Progression (POP) study.
Informed consent was obtained from all subjects and the entire
study was approved by the Duke University IRB. Participants met
